Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims are not supported by the provided JAVYGTOR prescribing information excerpts (e.g., Phase 3 trial numbers, responder proportions by dose, dose-optimization algorithm specifics, percentages, patent/generic and guideline mentions). Some safety elements (monitoring, hypophenylalaninemia, GI inflammation) are label-supported, but several dosing/titration and adverse-effect prevalence claims are either inconsistent with label excerpts or unsupported.
Category Scores
Accurate Statements
Sapropterin (BH4) is used to reduce blood phenylalanine levels in patients with BH4-responsive PKU, and it is used in conjunction with a Phe-restricted diet.
Section 1: indicated to reduce blood Phe levels in adults and pediatric patients 1 month of age and older with HPA due to BH4-responsive PKU; to be used in conjunction with a Phe-restricted diet; Section 2: all patients should also be treated with a Phe-restricted diet.
Monitoring of blood Phe levels during treatment is recommended.
Section 5.4: Frequent blood monitoring is recommended; Monitor blood Phe levels during treatment.
Some patients may experience hypophenylalaninemia (low blood Phe) during treatment.
Section 5.3: some PKU patients experienced hypophenylalaninemia during treatment.
Unsupported Statements
Therapeutic response varies with dose.
The provided label excerpts discuss biochemical response and dose adjustments based on blood Phe, but do not state a dose-response relationship in the specific way claimed.
Higher doses of sapropterin often yield better phenylalanine reduction in responsive patients.
Not supported by the provided label excerpts.
Patients are classified as responders if phenylalanine drops ≥30% from baseline on a restricted diet.
The label excerpt notes a ≥30% decrease response definition, but the claim specifies classification on a restricted diet; the provided excerpts do not explicitly combine both elements as stated.
In the Phase 3 PKU-004 trial, 20 mg/kg/day of sapropterin reduced phenylalanine by 37% on average over 6 weeks.
Specific Phase 3 study identifier (PKU-004) and numeric outcomes by dose are not provided in the supplied label excerpts.
In the Phase 3 PKU-004 trial, 10 mg/kg/day ... reduced phenylalanine by 27% on average over 6 weeks.
Specific trial name/number and dose-specific percent outcomes are not provided in the supplied label excerpts.
In the Phase 3 PKU-004 trial, 5 mg/kg/day ... reduced phenylalanine by 31% on average over 6 weeks.
Specific trial name/number and dose-specific percent outcomes are not provided in the supplied label excerpts.
About 20-25% of PKU patients respond to sapropterin.
A single overall response percentage is not provided in the supplied label excerpts.
Dose optimization identifies responders among partial cases.
Label describes a therapeutic trial/evaluation and biochemical response determination, but does not support this specific characterization.
Testing for sapropterin dosing starts at 10 mg/kg/day for 1 month.
Provided label excerpts specify recommended starting doses (10 mg/kg for 1 month to 6 years; 10 to 20 mg/kg for ≥7 years), but do not state a universal starting dose/testing protocol of 10 mg/kg/day for all patients.
Non-responders to sapropterin at 10 mg/kg/day stop treatment.
Provided label excerpt says if blood Phe does not decrease at 10 mg/kg/day the dose may be increased to 20 mg/kg/day; treatment is discontinued if no decrease after 1 month at 20 mg/kg/day.
Responders to sapropterin may titrate to 20 mg/kg/day.
Label supports dose increase to 20 mg/kg/day if no decrease at 10 mg/kg/day, and later adjustments 5–20 mg/kg/day based on biochemical response; it does not specifically support this as a responder-driven titration statement.
American College of Medical Genetics guidelines recommend a sapropterin challenge test.
Not supported by the provided label excerpts (professional society guideline statement is not part of the label sections provided).
Sapropterin response correlates with dose-dependent enzyme activation.
Label excerpt describes PAH hydroxylates Phe and BH4-responsive PKU with improvement in some patients; it does not provide this dose-dependent enzyme activation correlation.
Higher doses of sapropterin (up to 20 mg/kg) improve tolerance to dietary phenylalanine intake, allowing less restriction.
The provided excerpts do not mention dietary tolerance improvements or less restriction outcomes with higher doses.
A dose of 5 mg/kg/day ... associated with a mean phenylalanine reduction of 31% and a responder rate of about 20%.
Dose-specific percent reductions and responder rates at these doses are not provided in the supplied label excerpts.
A dose of 10 mg/kg/day ... associated with a mean phenylalanine reduction of 27% and a responder rate of about 20%.
Not supported by provided label excerpts.
A dose of 20 mg/kg/day ... associated with a mean phenylalanine reduction of 37% and a responder rate of about 25%.
Not supported by provided label excerpts.
Response to sapropterin depends on residual enzyme activity and BH4 cofactor sensitivity.
The label excerpt states PAH activity absent/deficient and BH4 responsive PKU but does not support this specific mechanistic claim.
Certain PAH mutations (e.g., p.R261Q) predict better high-dose response to sapropterin.
No mutation- or variant-specific predictive statements are included in the provided excerpts.
Non-responders often have null PAH mutations with no enzyme left.
Not supported by the provided excerpts.
Long-term studies show sustained benefits at optimized sapropterin doses.
No long-term sustained benefit data are provided in the supplied label excerpts.
About 50% of initial sapropterin responders lose efficacy over years.
Not supported by the provided label excerpts.
Doses above 20 mg/kg/day of sapropterin increase side effects including headache (13%).
The label excerpt does not provide side-effect incidence by dose, and 20 mg/kg/day dosing is the upper range mentioned; the claim references doses above 20 mg/kg/day and specific percentages not provided.
Doses above 20 mg/kg/day ... including pharyngitis (8%).
Not supported by provided label excerpts; no dose-specific incidence provided.
Higher doses of sapropterin are associated with transient phenylalanine spikes on discontinuation.
Not supported by the provided label excerpts.
No serious dose-related toxicity in trials up to 30 months of sapropterin.
Not supported by provided label excerpts.
Pediatric patients under 4 years show similar dose-response patterns to older children without added risks.
Label excerpt supports pediatric efficacy but does not support this cross-age dose-response and risk equivalence statement.
Key U.S. patents for sapropterin expire around 2029.
Not supported by prescribing information excerpts.
Generics of sapropterin may become available sooner via litigation.
Not supported by prescribing information excerpts.
Alternatives to sapropterin include pegvaliase (Palynziq) for adults unresponsive to sapropterin.
Not addressed in the provided JAVYGTOR label excerpts.
Pegvaliase achieves phenylalanine <600 μmol/L in 60% of adults unresponsive to sapropterin.
Not addressed in the provided JAVYGTOR label excerpts.
Pegvaliase efficacy is independent of dose.
Not addressed in the provided JAVYGTOR label excerpts.
Contradictions
High
AI Statement
Non-responders to sapropterin at 10 mg/kg/day stop treatment.
Label Reference
Section 2.2 (Biochemical response/discontinuation): If blood Phe does not decrease at 10 mg/kg per day, the dose may be increased to 20 mg/kg per day; discontinue if blood Phe does not decrease after 1 month at 20 mg/kg per day.
Important Omissions
The label’s explicit indication limits to BH4-responsive PKU patients and includes that treatment must be used with a Phe-restricted diet; several claims omit the 'in conjunction with diet' requirement even while discussing response and dosing.
Importance:
Moderate
Dose and administration details from the label (meal administration, once daily dosing, missed dose instruction, preparation volumes) were not addressed by the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
At least one dosing/discontinuation claim is contradicted by the label (stopping at 10 mg/kg/day rather than evaluating response at 20 mg/kg/day after increasing). Multiple other claims are unsupported, potentially leading to misinterpretation of dosing thresholds and incidence data; monitoring and hypophenylalaninemia are partly aligned.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several key dosing/response protocol claims and numeric trial outcomes are unsupported or contradicted by the provided label; additionally, multiple non-label assertions (guidelines, patents/generics, pegvaliase comparisons) are included.
Suggested Improvement
Remove or revise unsupported claims (trial identifiers, dose-specific percentages/responder rates, guideline/patent/generic/other-drug assertions). Align dosing/discontinuation and evaluation steps with Section 2.2 (increase to 20 mg/kg/day when no decrease at 10 mg/kg/day; discontinue only if no biochemical response after 1 month at 20 mg/kg/day). Include label-supported monitoring and diet requirements.